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the broad spectrum of affected spe-
cies, particularly raptors. A raptor was 
the index case in Denmark (7). Cur-
rent surveillance efforts in regions free 
from the virus favor investigation of 
signiﬁ  cant death events of waterfowl 
and active sampling of healthy water-
fowl as the means for early detection 
(e.g., 9). Many national surveillance 
programs are heavily inﬂ  uenced  by 
the inﬂ  uenza virus (H5N1) outbreak in 
2005 at Qinghai Lake in China, where 
hundreds of geese, gulls, and cormo-
rants died during the breeding season 
(10). However, large die-offs may be 
anomalous or restricted to communal 
breeding sites of waterfowl where ju-
venile birds amplify and spread the vi-
rus within the breeding colony. Testing 
of public-reported singleton carcasses 
provides a more sensitive and robust 
means of early detection of this virus.  
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Klebsiella 
pneumoniae 
Carbapenemase–2, 
Buenos Aires, 
Argentina
To the Editor: The activity of 
carbapenem has been compromised 
because of the emergence of carbap-
enemases (1). Since 1995, carbapenem 
resistance has been identiﬁ  ed among 
77 Klebsiella pneumoniae isolates and 
1 Citrobacter freundii clinical isolate 
in Argentina (WHONET-Argentina 
Network). However, until now, none 
had produced a carbapenemase.
K. pneumoniae carbapenemase-1 
(KPC-1) was ﬁ   rst detected in a K. 
pneumoniae strain isolated in North 
Carolina in 2001 (1). Since that time, 
several reports of KPCs worldwide 
have been made, including in South 
America (1). We report on KPC-2
–producing K. pneumoniae and C. fre-
undii clinical isolates in Argentina.
A 36-year-old woman with sys-
temic lupus erythematosus and chron-
ic renal failure was admitted to the 
Sanatorio Mitre in Buenos Aires in 
September 2006 for a kidney trans-
plant. Two months after the transplant, 
intraabdominal collection obtained 
during a surgical procedure yielded a 
carbapenem-susceptible  Escherichia 
coli isolate, after which meropenem 
therapy was initiated (1 g/day). After 
16 days of treatment, an infection de-
veloped at the patient’s surgical site 
(per US Centers for Disease Control 
and Prevention criteria, available from 
www.cdc.gov/ncidod/dhqp/pdf/guide
lines/SSI.pdf).  C. freundii M9169 
and K. pneumoniae M9171 were both 
isolated from the same specimen ob-
tained from the surgical site. Because 
carbapenemase production was sus-
pected, carbapenem treatment was 
stopped, and the infection was treated 
with local antiseptic and drainage for 
20 days; the patient was discharged 
from the hospital in January 2007. 
Neither the patient nor her relatives or 
hospital staff had been in the United 
States before the emergence of these 
strains.
By using disk diffusion (2) (Mu-
eller-Hinton agar and disks obtained 
from Difco and BBL, respectively; 
Becton, Dickinson and Co., Frank-
lin Lakes, NJ, USA), we determined 
that K. pneumoniae M9171 was resis-
tant to all antimicrobial drugs except 
amikacin, tetracycline (3), and tigecy-
cline (US Federal Drug Administra-
tion criteria, susceptible >19 mm ). C. 
freundii M9169 remained susceptible 
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to carbapenems, cefepime, ciproﬂ  oxa-
cin, aminoglycosides, chlorampheni-
col, tetracyclines, and tigecycline but 
displayed resistance to ceftazidime 
(CAZ), cefotaxime (CTX), nalidixic 
acid, and trimethoprim-sulfamethox-
azole. When tested with an AmpC-
type  β-lactamase inhibitor (4), both 
strains showed synergism between 
3-aminophenylboronic acid (APB, 
Sigma-Aldrich, St. Louis, MO, USA) 
disks and CTX, CAZ, and carbapen-
ems when placed 20 mm apart (center 
to center). The same synergism was 
observed for K. pneumoniae D5/07, 
a reference KPC-2–producing strain 
(College of American Pathologists 
Quality Control Assurance Program), 
but not among E. coli ATCC 25922. A 
CMY-2–producing K. pneumoniae C2 
control strain (5) displayed APB syn-
ergism against only CTX and CAZ, 
not carbapenems.  
The MICs of carbapenems (6) 
(agar dilution), conﬁ  rmed disk diffu-
sion results showing a >3 doubling-
dilution decrease after the addition 
of APB (300 μg/mL) for K. pneumo-
niae M9171, C. freundii M9169, and 
K. pneumoniae D5/07, but not for K. 
pneumoniae C2 and E. coli ATCC 
25922. Clavulanate (4 μg/mL) reduced 
only meropenem and ertapenem, and 
imipenem MICs of C. freundii M9169 
and K. pneumoniae D5/07, respective-
ly (Table). 
Isoelectric focusing (IEF) showed 
that both isolates produced several 
β-lactamases (Table), including a 
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Table. Antimicrobial drug susceptibility, isolectric focusing of ȕ-lactamases and PCR of antimicrobial resistance determinants in 
Klebsiella pneumoniae, Citrobacter freundii clinical isolates, Salmonella transconjugants, and recipient and control strains* 
Clinical isolates  Transconjugants and recipient strains  Control strains 
Type of testing 
K.p.
M9171 
C.f.
M9169 
Salmonella 
M9204† 
Salmonella 
M9190‡ 
Salmonella 
M1744 
K.p.
D5/07§ 
K.p.
C2¶ 
E. coli ATCC 
25922
  MICs (μg/mL) 
Antimicrobial agent                     
 Imipenem  32 1.0   1.0  1.0  0.12    2.0  0.12  0.25 
 Impenem/clavulanate  32 0.25   0.25  0.25  0.12    0.5  0.12  0.25 
 Impenem/APB  2.0 0.12   0.25  0.12  0.12    0.12  0.12  0.25 
 Imipenem/EDTA#  32 0.25   1.0  1.0  0.12    2.0  0.12  0.12 
 Meropenem  32 1.0   0.5  1.0  0.015    2.0  0.03  0.03 
 Meropenem/clavulanate  32 0.12   0.03  0.06  0.015    1.0  0.03  0.03 
 Meropenem/APB  1.0 0.06   0.03  0.03  0.015    0.12  0.03  0.03 
 Meropenem/EDTA#  32 1.0   0.5  1.0  0.015    2.0  0.03  0.03 
 Ertapenem  128 2.0   1.0  1.0  0.008    16 0.06  0.015 
 Ertapenem/  clavulanate  128 0.25   0.03  0.06  0.008    16 0.06  0.008 
 Ertapenem/APB  8.0 0.008   0.015  0.03  0.008    0.5 0.03  0.008 
 Cefoxitin  64 64    4.0  8.0  2.0    ND  ND  4 
 Ceftazidime  256 16   16  32  0.06    ND ND  0.25 
 Ceftazidime/clavulante  16 32    0.5  0.5  0.06    ND  ND  ND 
 Cefepime  32 4.0   16  16  0.03    ND  ND  0.03 
 Cefepime/clavulanate  16 0.25   0.5  0.25  0.03    ND ND  ND 
 Tigecycline** 1.0 0.25    ND  ND  ND   ND ND  0.25 
  Isolectric focusing results 
pI band††  5.4 + 6.7 
+ 7.6 
5.4 + 
6.7 + 
>9.0 
 6.7  6.7  None   ND  ND  None 
  PCR results 
ȕ-lactamase                  
 blaKPC  + +    +  +  –    + –  ND 
 blaampC – +   
CIT/ 
CMY 
 –  –  –    –  +   
CIT/ 
CMY 
ND 
 blaPER-2  + –    –  –  –    ND  ND  ND 
 blaSHV  + –    –  –  –    ND  ND  ND 
 blaTEM-1  + +    –  –  –    ND  ND  ND 
*K.p., Klebsiella pneumoniae; C.f., Citrobacter freundii; E. Coli, Escherichia coli; APB, 3-aminophenylboronic acid; IEF, isoelectric focusing; pI, isoelectric 
point; ND, not determined; +, positive; –, negative. 
†M9204 transconjugant derived from K. pneumoniae M9171.  
‡M9190 transconjugant derived from C. freundii M9169. 
§Control strain producing KPC-2. 
¶Control strain producing CMY-2. 
#EDTA 0.4 mmol/L. 
**Microdilution (JustOne, Trek Diagnostic Systems, Cleveland, OH, USA). Breakpoints according to US Food and Drug Administration (susceptible  
<2 ȝg/mL).  
††Underlined pI bands indicated activity against third-generation cephalosporins. LETTERS
common enzyme with ESBL activity 
(isoelectric point [pI] 6.7 by a sub-
strate-based iodometric method) (7). 
K. pneumoniae M9171  coproduced 
another ESBL band at pI 5.4 (7).  
Beta-lactamases were charac-
terized by PCR speciﬁ   c for KPC 
(forward primer 5′-AACAAGGAATA
TCGTTGATG-3′; reverse primer 5′-
AGATGATTTTCAGAGCCTTA-3′), 
PER-2, SHV, and TEM (7). Both 
strains were PCR-positive for KPC 
and TEM. PER-2 and SHV were am-
pliﬁ  ed in K. pneumoniae M9171. Be-
cause of the APB inhibition observed, 
strains were tested for plasmid-medi-
ated AmpC genes (8). The amplicon 
for the CIT/CMY primers was ob-
served for C. freundii M9169 (expect-
able cross-ampliﬁ   cation with chro-
mosomal AmpC) (Table). KPC-type 
PCR product (916 bp) obtained from 
K. pneumoniae M9171 was sequenced 
and identiﬁ  ed as KPC-2 (1).
A wild-type Salmonella clinical 
isolate (M1744) was chosen for con-
jugational purpose because it naturally 
lacks AmpCs . Conjugation resulted in 
the transfer to M1744 of penicillins 
and third-generation cephalosporin 
resistance from both clinical isolates 
(frequency 10–4 to 10–5, when selected 
with ampicillin [50 μg/mL] in Salmo-
nella–Shigella medium). Transcon-
jugants showed the acquisition of an 
≈70-kb plasmid, which was present in 
both clinical isolates (9). Transconju-
gants displayed an APB double-disk 
augmentation trait, further observed 
by MIC. Only the KPC enzyme was 
transferred (unique band at pI 6.7) by 
IEF, which was conﬁ   rmed by PCR. 
The absence of plasmid-mediated 
AmpC genes was conﬁ  rmed by PCR 
(Table). No other resistances to non–
β-lactam agents were cotransferred.
Carbapenemase activity of crude 
extracts was measured at 30°C by fol-
lowing 0.4 mmol/L imipenem or er-
tapenem hydrolysis at 300 nm in 10 
mmol/L HEPES (pH 7.5). Addition of 
4 mmol/L APB resulted in inhibition 
of carbapenemase activity of K. pneu-
moniae M9171, C. freundii M9169, 
both transconjugants, and K. pneumo-
niae D5/07, but not a VIM-11 control 
run in parallel (10). 
This study identiﬁ  ed  KPC 
β-lactamase, which was possessed by 
2 strains recovered from 1 patient, in 
Argentina. Detection of this carbap-
enemase could become cumbersome 
because carriage of these genes does 
not always confer obvious resistance. 
Moreover, an unusual phenotype was 
observed in this study; boronic inhibi-
tion was associated with the sole pres-
ence of KPC. Microbiologists should 
be aware of cross-reactions (syner-
gism) between APB and KPC that 
could lead to the false assumption of 
AmpC-type  β-lactamase production, 
thereby underestimating the presence 
of this carbapenemase.   
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